These are top 10 stocks traded on the Robinhood UK platform in July
In a challenging year for Flex (NASDAQ:FLEX) Pharma Inc., the company’s stock (SLRX) has recorded a new 52-week low, dipping to $0.7. According to InvestingPro data, the stock’s RSI indicates oversold territory, while the company maintains a market cap of $1.22 million with more cash than debt on its balance sheet. This latest price level reflects a significant downturn in the company’s market performance, with the stock experiencing a precipitous 1-year change, plummeting by -82.01%. Investors have been closely monitoring SLRX as it struggles to find a foothold in a volatile market, with the current low representing a critical juncture for the company’s financial outlook and investor confidence. InvestingPro analysis suggests the stock is currently undervalued, with the next earnings report expected on May 12, 2025. Subscribers can access 12 additional ProTips and comprehensive financial metrics to better evaluate SLRX’s potential.
In other recent news, Salarius Pharmaceuticals has amended its merger agreement with Decoy Therapeutics, setting fixed ownership percentages post-merger, with Salarius stockholders owning 14.1% and Decoy’s owning 85.9% of the combined entity. This amendment disregards previous balance sheet cash adjustments. Additionally, Salarius received a notice from Nasdaq about not meeting the minimum stockholders’ equity requirement, necessitating a compliance plan submission by May 12, 2025. In a separate development, Salarius has initiated a registered offering of common stock shares valued at up to $417,000 under an existing agreement with Ladenburg Thalmann & Co. Inc.
The company has resumed patient enrollment in a Phase 1/2 clinical trial for seclidemstat, an oral inhibitor for treating myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), after addressing FDA concerns that previously halted the trial. Interim results showed a 43% overall response rate among patients with higher-risk MDS and CMML. Salarius also announced plans to merge with Decoy Therapeutics, aiming to leverage Decoy’s IMP3ACT™ platform for peptide conjugate therapeutics. The combined company plans to incorporate Salarius’s SP-3164 into a drug candidate, reflecting ongoing clinical and corporate strategies to advance its pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.